ECSP10010516A - Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares - Google Patents

Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares

Info

Publication number
ECSP10010516A
ECSP10010516A EC2010010516A ECSP10010516A ECSP10010516A EC SP10010516 A ECSP10010516 A EC SP10010516A EC 2010010516 A EC2010010516 A EC 2010010516A EC SP10010516 A ECSP10010516 A EC SP10010516A EC SP10010516 A ECSP10010516 A EC SP10010516A
Authority
EC
Ecuador
Prior art keywords
igf
treatment
neuromuscular disorders
pegylated
variants
Prior art date
Application number
EC2010010516A
Other languages
English (en)
Inventor
Friedrich Metzger
Bettina Holtmann
Michael Sendtner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41021043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP10010516A publication Critical patent/ECSP10010516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere el uso farmaceutico de variantes del IGF-I modificado con polietilenglicol (=PEGilado) para el tratamiento, prevencion y/o demora de la progresion de trastornos neuromusculares, en particular de la esclerosis lateral amiotrofica (ELA). Mas especificamente, la presente invencion se refiere al uso de una variante de IGF-I PEGilada para la fabricacion de una composicion farmaceutica destinada al tratamiento, prevencion y/o demora de trastornos neuromusculares, en particular de la ELA, dicha variante de IGF-I PEGilada se caracteriza porque se deriva de la secuencia de aminoacidos del IGF-I humano de tipo salvaje (SEQ ID NO: 1) y lleva una o dos alteraciones de aminoacido en las posiciones 27, 65 y 68, de modo que uno o dos de los aminoacidos de las posiciones 27, 65 y 68 sea o sean aminoacidos polares, pero no la lisina, y el PEG esta unido por lo menos a un resto lisina.
EC2010010516A 2008-04-03 2010-10-01 Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares ECSP10010516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08153994 2008-04-03

Publications (1)

Publication Number Publication Date
ECSP10010516A true ECSP10010516A (es) 2010-11-30

Family

ID=41021043

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010516A ECSP10010516A (es) 2008-04-03 2010-10-01 Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares

Country Status (19)

Country Link
US (5) US20090253628A1 (es)
EP (1) EP2274016B1 (es)
JP (1) JP5173018B2 (es)
KR (1) KR101273187B1 (es)
CN (1) CN101983074A (es)
AR (1) AR071574A1 (es)
AU (1) AU2009231394B2 (es)
BR (1) BRPI0910338A2 (es)
CA (1) CA2720408C (es)
CL (1) CL2009000803A1 (es)
CR (1) CR11692A (es)
EC (1) ECSP10010516A (es)
ES (1) ES2388827T3 (es)
IL (1) IL208106A (es)
MX (1) MX2010010495A (es)
PE (1) PE20091715A1 (es)
RU (1) RU2010144014A (es)
TW (1) TW200944237A (es)
WO (1) WO2009121759A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CN101484469B (zh) 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
KR20100119899A (ko) * 2008-04-03 2010-11-11 에프. 호프만-라 로슈 아게 폴리에틸렌글리콜화된 인슐린 유사 성장 인자 분석법
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
WO2012178146A1 (en) * 2011-06-24 2012-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of spinal muscular atrophy
KR102499918B1 (ko) * 2012-10-24 2023-02-14 다이이찌 산쿄 가부시키가이샤 근위축성 측삭 경화증 치료제
BR112016005716A2 (pt) 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
BR112019022789A2 (pt) 2017-05-30 2020-06-09 Teijin Pharma Ltd anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico.
AU2018317807A1 (en) * 2017-08-16 2020-02-06 Roxiant ApS VTFT isoform of a BPIFB4 protein for use in neuronal diseases and injuries
MY205006A (en) 2018-12-03 2024-09-27 Teijin Pharma Ltd Anti-igf-i receptor humanized antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
WO1995032003A1 (en) * 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
DE60042550D1 (de) * 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CN101484469B (zh) * 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法

Also Published As

Publication number Publication date
AR071574A1 (es) 2010-06-30
CL2009000803A1 (es) 2010-05-07
EP2274016B1 (en) 2012-07-25
KR20100119816A (ko) 2010-11-10
TW200944237A (en) 2009-11-01
CN101983074A (zh) 2011-03-02
BRPI0910338A2 (pt) 2020-08-18
IL208106A (en) 2015-09-24
WO2009121759A3 (en) 2010-03-25
JP5173018B2 (ja) 2013-03-27
AU2009231394B2 (en) 2013-09-05
AU2009231394A1 (en) 2009-10-08
US20150273023A1 (en) 2015-10-01
CR11692A (es) 2010-12-09
WO2009121759A2 (en) 2009-10-08
MX2010010495A (es) 2010-10-15
CA2720408A1 (en) 2009-10-08
RU2010144014A (ru) 2012-05-27
EP2274016A2 (en) 2011-01-19
JP2011518778A (ja) 2011-06-30
US20170014488A1 (en) 2017-01-19
PE20091715A1 (es) 2009-11-17
CA2720408C (en) 2016-09-06
US20090253628A1 (en) 2009-10-08
US20110183903A1 (en) 2011-07-28
ES2388827T3 (es) 2012-10-19
IL208106A0 (en) 2010-12-30
KR101273187B1 (ko) 2013-06-17
US20140073567A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
MX340541B (es) Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EA201790871A1 (ru) Нацеленные конъюгатные композиции xten и способы их получения
AR071574A1 (es) Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromusculares
BRPI0515118A (pt) conjugados de hormÈnio do crescimento humano com polietileno glicol
CL2018003697A1 (es) Interferón porcino pegilado y métodos de uso del mismo.
HK1215934A1 (zh) 肽治疗剂及其使用方法
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
MD20140134A2 (ro) Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
BR112014007675A2 (pt) tratamento de doença articular degenerativa
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CL2008002390A1 (es) Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer.
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
PL1940381T3 (pl) Farmaceutyczne kompozycje do oczu oparte na aminokwasach i hialuronianie sodu
CL2017003201A1 (es) Variantes de il-37
CO2018011586A2 (es) Inhibidor de esterasa c1 conjugado y sus usos
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
EP3026057A3 (en) Compositions for prevention and treatment of neurodegenerative diseases
BR112013027369A2 (pt) composições e métodos
BRPI0401908A (pt) Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses